Myotonic dystrophy (DM1) is caused by the expansion of a trinucleotide repeat (CTG) located in the 3 0 untranslated region of the myotonic dystrophy protein kinase gene, for which currently there is no effective treatment. The data available suggest that misregulation of RNA homeostasis may play a major role in DM1 muscle pathogenesis. This indicates that the specific targeting of the mutant DMPK transcripts is essential to raise the rationale basis for the development of a specific gene therapy for DM1. We have produced a retrovirus which expresses a 149-bp antisense RNA complementary to the (CUG)13 repeats and to the 110-bp region following the repeats sequence to increase the specificity. This construct was introduced into human DM1 myoblasts, resulting in a preferential decrease in mutant DMPK transcripts, and effective restoration of human DM1 myoblast functions such as myoblast fusion and the uptake of glucose. It was previously shown that delay of muscle differentiation and insulin resistance in DM1 are associated with misregulation of CUGBP1 protein levels. The analysis of CUGBP1 levels and activity in DM1 cells expressing the antisense RNA indicated a correction of CUGBP1 expression in infected DM1 cells. We therefore show that current antisense RNA delivered in vitro using a retrovirus is not only capable of inhibiting mutant DMPK transcripts, but also can ameliorate dystrophic muscle pathology at the cellular levels. Gene Therapy (2003) 10, 795-802.
Introduction
Myotonic dystrophy (DM1) is the most common form of inherited neuromuscular disorder in adults with a global incidence of about one in 8500 individuals. 1 The genetic basis for this autosomal-dominant disease is an expanded trinucleotide repeat (CTG) located in the 3 0 -untranslated region (3 0 UTR) of the dystrophy myotonic protein kinase (DMPK) gene. [2] [3] [4] At the molecular levels, the DM1 phenotype is most likely caused by a complex molecular pathogenesis, including deficiency of myotonic dystrophy myotonin kinase (DMPK) protein, [5] [6] [7] haplo-insufficiency of a neighboring homeobox gene (particular the DM locus-associated homeodomain protein (DMAHP/Six 5 gene) 8 and the WD-repeat gene (DMWD) 9 and a trans-dominant misregulation of RNA homeostasis. [10] [11] [12] [13] [14] [15] [16] Recent experiments from transgenic mice, expressing an untranslated expanded CUG repeat under the control of the human skeletal actin promoter, showed that expanded CUG repeats are sufficient to generate DM1 muscle phenotype. 17 These data suggest that misregulation of RNA homeostasis may play a major role in DM1 muscle pathogenesis. This indicates that the specific targeting of the mutated DMPK transcripts is essential to raise the rationale basis for the development of a specific gene therapy for DM1, at least for muscle weakness and wasting.
Gene silencing has been achieved with varying efficiencies using antisense DNA or RNA, ribozymes and more recently siRNAs. [18] [19] [20] [21] The antisense RNA technology utilizes ribonucleic acids that, like antisense oligonucleotides, bind by complementary interactions with a specific target mRNA (in this case forming RNA:RNA hybrids) and subsequently either block one of the several steps involved in the translation of a targeted protein or induced destruction of the target RNA most likely by activating an endonuclease activity following deamination of dsRNA by an adenosine deaminase. 22, 23 Expression vectors producing antisense RNA have major advantages over the oligonucleotides in that, since vectors can synthesize the antisense RNA continuously inside the cell after a single administration, it would have a longer duration of action.
We have therefore designed, constructed and evaluated the effect of an antisense RNA directed complementary to (CUG)13 repeat sequence and to the 110-bp sequence, following the expansion, using a vector derived from Moloney murine leukemia virus (M-MLV), for use in human DM1 myoblasts. We demonstrated that expression of antisense CUG in DM1 muscle cells is able to correct delay of muscle fusion and insulin resistance via normalization of CUGBP1 levels.
Results
Construction of recombinant retrovirus expressing (CUG)13 antisense RNA Based on the results obtained with antisense oligonucleotides, we have developed a retrovirus (pLXie(-CUG) 13 ) containing a DMPK antisense cDNA of 149 bp (CUG)13 complementary to 13 CUG repeats and 110 bp in the following region and under the control of the 5 0 LTR (Figure 1 ). Another antisense construct (pLXie5 0 UTR) was generated against a 875-bp region in the 5 0 UTR of the DMPK mRNA. All these retrovirus also contain the GFP gene for cell selection (Figure 1) . A retrovirus expressing the GFP gene (pLXie) alone was used as control.
Expression of RNA antisenses and effects on DMPK mRNA DM1 and normal muscle cells used in this study were purified by cell sorting using a neural cell adhesion molecule (N-CAM) antibody as described previously. 24 More than 90% of DM1 and normal cells were desminpositive, indicating that they are myoblasts. DM1 myoblasts were infected with recombinant retrovirus, and GFP-positive cells were selected by FACS after 5 days. Cells were grown in permissive medium until confluence and then were shifted to differentiating medium. Under these conditions, more than 99% of the cells were GFP-positive. The levels of transgene expression were determined by Northern blot. As shown in Figure 2a , the 5 0 UTR and (CUG)13 antisense RNAs were expressed at high levels in human DM1 cells, at day 5 of differentiation. In further experiments, we analyzed the levels of DMPK mRNAs in human DM1 cells expressing the 5 0 UTR, (CUG)13 antisenses RNA and the GFP gene ( Figure 2b ). In normal myoblasts, the probe detected one 3.3-kb mRNA, which is the expected size of the DMPK mRNA. In DM1 myoblasts, the probe detected a 3.3-kb mRNA and a higher RNA band of approximately 5.6 kb, which correspond to the expanded transcripts, containing 750 CUG repeats. We found that in DM1 cells expressing the antisense RNA against the CUG repeat sequence, the levels of the mutant and normal DMPK mRNAs were decreased by 80 and 50%, respectively, when compared to noninfected DM1 cells (levels of the wild-type DMPK mRNA: 6.270.5, 0.970.17 arbitrary unit in DM1 and pLXie(CUG) 13 DM1 myoblasts, respectively; levels of the mutant DMPK mRNAs: 3.970.5 and 0.970.17 arbitrary unit in DM1 and pLXie(CUG) 13 DM1 myoblasts, respectively). In contrast, no effect of 5 0 UTR antisense RNAs on DMPK mRNAs was observed (P40.36). The levels of DMPK mRNA remained unchanged in cells expressing the GFP gene (P40.43). From these data, we concluded that (CUG)13 antisense vector inhibits both normal and mutant DMPK mRNA, however, there was a more important inhibition of mutant than normal DMPK mRNAs.
Restoration of DM1 myoblast differentiation by antisense RNA DM1 myoblasts were infected with recombinant retrovirus, and GFP-positive cells were selected by FACS after 5 days. To determine whether antisense RNA induces 0 UTR and pLXie(CUG)13 retrovirus were subjected to electrophoresis and hybridized with a GFP DNA probe. This probe detected mRNAs that correspond to the size of 5 0 UTR-GFP and (CUG)13-GFP mRNAs, respectively. (b) Expression of DMPK mRNAs determined by Northern blot from DM1 myoblasts transduced with pLXie5 0 UTR, PLXie and PLXie(CUG)13, and from uninfected DM1 and normal myoblasts. In all, 20 mg of total RNAs were subjected to electrophoresis and hybridized with a cDNA DMPK probe. Blots were normalized for RNA loading by reprobing with a 32 P-labeled probe for cyclophilin. (c) Quantitation of DMPK mRNA expression. The graph shows the mean7SD of three independent experiments. ** and ***, significantly different from nontransduced DM1 myoblasts, P¼0.003 and 0.001, respectively (student's t-test).
Targeting of mutant DMPK transcripts D Furling et al apoptosis, noninfected and infected human myoblasts were stained with both 7-amino-actinomycin D (7-AAD) and phycoerythrin-labeled annexin V (annexin V-PE), which preferentially binds to phosphatidylserine residues. The exposure of phosphatidylserine on the outside of the plasma membrane is an early event characteristic of the apoptotic process, preceding the loss of integrity of the plasma membrane. Cell annexin V-PE positive and 7-AAV negative were considered as apoptotic, and their percentage was calculated ( Figure 3a ). No significant difference was observed between the number of annexin V-PE-positive cells in noninfected and infected DM1 myoblasts with pLXie (CUG) 13 antisense (2.271.4 and 1.870.4%, for noninfected and infected DM1 myoblasts, respectively; n¼3, P¼0.39), indicating that antisense RNA did not induce apoptosis. The proliferating infected DM1 myoblasts are typically spindle shaped and have a morphology very similar to the proliferating normal myoblasts or uninfected DM1 myoblasts. The growth of normal, DM1 and DM1-infected myoblasts in proliferative medium was determined by MTT assay. As shown in Figure 3b , the growth of normal and DM1 myoblasts was very similar, with a doubling time of about 36 h, as previously reported. 25 The growth of DM1 myoblasts expressing either 5 0 UTR antisense RNAs or (CUG)13 antisense RNAs or the GFP gene was also similar with that of noninfected DM1 myoblasts. This indicates that the antisense vector has no toxic effect on DM1 cells. When DM1 cultures were switched from permissive to nonpermissive conditions, the majority of cells ceased DNA synthesis by 48 h; myotube formation began within 3 days of switching to nonpermissive conditions, and they continued to increase in size and number over several days. The quality of the differentiation of infected DM1 myoblasts was compared with uninfected DM1 and normal myoblasts. The index of fusion was much lower in DM1 cultures than in the controls (5972% versus 8875%), and it was very similar for DM1 myoblasts infected or not with retrovirus producing 5 0 UTR antisense RNAs or the GFP gene (Table 1 ). In contrast, the fusion index of DM1 myoblasts infected with a retrovirus expressing (CUG)13 antisense RNA was restored to the level of normal myoblasts (8675% versus 8875%). In addition, the myotubes formed by both types of cultures showed striking differences. The normal myoblasts formed large branched myotubes with several nuclei (Figure 4e ), whereas DM1 myotubes were much smaller and had a relatively small number of nuclei per myotube ( Figure  4c ). Thus, after 5 days of differentiation, control cultures showed an average of 1572 nuclei per myotube, whereas DM1 myotubes contained an average of 3.870.5, 3.570.4 and 3.570.3 nuclei per myotube in uninfected, infected with retrovirus producing 5 0 UTR antisense, or the GFP gene, respectively (Table 1 ). In DM1 cell cultures infected with the retrovirus producing (CUG) 13 antisense RNAs, myotubes were much bigger and contained as many nuclei (1371) as observed in control cultures (Figure 4d , Table 1 ).
Defective action of insulin in DM1 cells is circumvented by antisense RNA
Insulin resistance is the principal metabolic abnormality associated with the pathology of DM1, and we Targeting of mutant DMPK transcripts D Furling et al previously showed that insulin resistance is retained in human DM1 myoblast culture. 26 To determine whether antisense RNA can circumvent defective insulin action in human DM1 myoblasts, we analyzed the influence of insulin on glucose uptake. In DM1 cells, a dose of 10 and 50 nM insulin produced no stimulatory effect on glucose uptake as reported previously. 26 In contrast, 10 and 50 nM insulin produced a two-fold increase in the uptake of glucose in DM1 cells producing (CUG)13 antisense RNAs ( Figure 5 ).
CUGBP1 levels in Infected DM1 cells
It has been previously reported that CUGBP1 levels and RNA-binding activity are increased by expansion of CUG repeats in DM1 patients and in DM1 cell culture models. [11] [12] [13] This deregulation of CUGBP1 results in delay of skeletal muscle differentiation and insulin resistance in DM1 disease. Since the expression of antisense RNA restored efficiency of muscle differentiation and glucose uptake (Figures 4 and 5 , and Table 1) , we next examined whether the antisense RNA brings CUGBP1 expression to the normal levels. Western analysis of whole cell protein extracts with antibodies against CUGBP1 shows that the total levels of CUGBP1 protein are increased by 3.2-fold in DM1 myoblasts, and the expression of antisense RNA reduces CUGBP1 to normal levels (Figure 6a ). Expression of antisense RNA did not affect global protein expression because the reprobing of the same membrane with antibodies to bactin shows no change in b-actin levels (Figure 6a ). Normalization of CUGBP1 total levels in DM1 cells by expression of RNA CUG antisense suggested that 
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CUGBP1-binding activity is also corrected. To examine RNA-binding activity of CUGBP1, equal amounts of total proteins from normal and DM1 myoblasts as well as from DM1 myoblasts treated with antisense were examined by UV-crosslink assay with the RNA probe containing 123 CUG repeats (Figure 6b ). In normal myoblasts, only one CUGBP1 complex was detected with this probe. In agreement with the data obtained by Western analysis, RNA-binding activity of CUGBP1 is 3-4-fold induced in DMI myoblasts. In addition to CUGBP1/CUG 123 complex, UV-crosslink also revealed a weak CUG-binding complex that is not detectable in normal cells. Expression of antisense in DM1 cells completely inhibits the activity of both CUG-binding complexes (Figure 6b ). Complete inhibition of CUGBP1 activity in the cells containing antisense could not be explained by the lack of CUGBP1 protein because Western blot shows normal levels of CUGBP1 in treated cells (Figure 6a ). Inability to detect CUGBP1 by UVcrosslink in treated cells is not caused by protein degradation because Coomassie staining of the same membrane after UV-crosslink indicated the presence of equal amounts of proteins in all samples. Thus, we suggest that the reduction of CUGBP1 activity in DM1-treated cells is partially because of reduced total levels of CUGBP1. The complete inhibition of CUGBP1 activity determined by UV-crosslink assay is perhaps associated with competition of antisense RNA, which is present in protein extracts from treated cells. Thus, antisense RNA corrects CUGBP1 total protein levels in DM1 myoblasts.
Discussion
Antisense RNA is a potentially powerful tool for gene silencing. Several issues however have limited wider use of antisense technology. Problems have included a lack of suitable target sequences within a given mRNA caused by RNA secondary folding, which necessitate screening of multiple antisense sequences to identify those that mediate the greatest level of inhibition, and insufficiency delivery in vitro and in vivo. Despite insufficiency delivery in vitro, we found that retrovirus produced high levels of antisense in human myoblasts cultures.
Another potential limitation of the use of antisense RNA technology is that they formed RNA:RNA hybrids (dsRNA) in cells which is sufficient to elicit an antiviral response mediated by enzymes such as dsRNA-dependent protein kinase (PKR) 27,28 or 2 0 -5 0 -oligoadenylate synthetase/RNase L, 29, 30 which induce apoptosis. Our data do not support an activation of PRK by dsRNA since no apoptosis was observed in infected cells.
DM1 is caused by the expansion of a CTG trinucleotide repeat on chromosome 19q13.3. There are several evidences suggesting that the nuclear accumulation of Figure 5 Comparison of glucose transport activity in normal, DM1 and infected DM1 pLXie (CUG)13) myoblasts. Cells were incubated with aMEM depleted in insulin for 24 h and then incubated in the absence or presence of insulin. Cells were then washed, and 2-deoxyglucose uptake was measured. Results are the mean7SD of three different experiments. Each experiment was performed in triplicate. **, Po0.003; ns, not significant (by student's t-test). 
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RNAs from the mutant transcripts 31 may play a major role in the pathogenesis of DM1 muscle. This indicates that the specific destruction of the mutated DMPK transcripts may be essential to restore normal DM1 myoblast functions.
We previously reported that the proliferation rate of diseased myoblasts remains unaffected; however, their differentiation program was altered. 25, 32 Here we showed that retrovirus producing (CUG) 13 antisense RNA has no effect on the proliferative rate of DM1 myoblasts; however, it restores the differentiation of infected DM1 myoblasts as indicated by the increase in the fusion index, in the mean number of nuclei per myotube as well as in the uptake of glucose. The specificity of these effects is supported by the fact that two other retrovirus producing the GFP protein or an antisense RNA against the 5 0 UTR have no effect on the levels of DMPK mRNAs nor on the growth and differentiation of DM1 myoblasts. Here we showed that in infected DM1 myoblasts, the (CUG)13 RNA antisense inhibits both the mutant and the normal DMPK transcripts, although at different levels (80 versus 50%, respectively). The strong reduction of the mutated DMPK transcripts by the (CUG)13 antisense could explain the restored differentiation of the infected DM1 myoblasts. This possibility is also supported by the recent report of Timchenko et al 33 showing that alterations in the activity of the CUGBP1 by the mutant DMPK transcripts causes disruption of p21-dependent control of cell cycle arrest, rendering DM1 myoblasts incapable of withdrawing from the cell cycle and fuse to form myotubes. We demonstrated that the misregulation of the CUG-binding protein in DM1 myoblasts was corrected in the antisense-infected DM1 myoblasts, indicating that molecular alterations induced by the mutated DMPK transcript were reversed by the expression of the (CUG) 13 antisense in DM1 cells. In addition, it has been suggested that the insulin resistance that occurs in DM1 muscles may be the consequences of alteration in the splicing of insulin receptor pre-mRNA caused by the increased expression of CUG-binding proteins. 34 We showed that the defective action of insulin on glucose uptake retained in DM1 muscle cell cultures was also completely restored in (CUG) 13 antisense-infected DM1 myoblasts. Thus, decreased levels of mutant DMPK transcripts by the antisense inhibit the abnormal upregulation of the total levels of CUG-binding protein that may counteract the aberrant regulation of the insulin receptor and restore the action of insulin on glucose uptake in DM1 myoblasts. Normalization of CUGBP1 levels in DM1 differentiating myoblasts expressing RNA CUG antisense supports the idea that antisense expression vector is able to correct misregulated pathways caused by mutant DMPK mRNA.
To improve antisense gene therapy, it would be necessary to target specifically the mutant DMPK mRNAs. The most logical approach to target specifically these transcripts would be the design of antisense RNAs, which has a nuclear localization, by using nuclear promoters such as tRNA meti or Pol III. Taken as a whole, our data indicate that the decreased levels in mutant DMPK mRNAs are essential to restore DM1 myoblast functions. Our data support a future role for antisense expression vectors as a new gene therapy for myotonic dystrophy. In addition, our data also support that a mRNA encoding for a gene reporter linked to an antisense RNA does not prevent the inhibition of gene expression by the antisense RNA.
Materials and methods

Muscle cells
Human myoblasts were maintained and expanded at 371C in the proliferative medium MCDB120 supplemented with 15% fetal bovine serum. The percentage of myogenic cells in the culture was determined by immunocytochemistry analysis using anti-desmin antibody as described previously. [24] [25] [26] Southern blot analysis showed a length of CTG repeats of about 750 in DM1 myoblasts. 25 For myoblast differentiation, cells were subsequently cultured in a-MEM supplemented with 10 mg/ml insulin, 10 ng/ml epidermal growth factor and 0.5 mg/ml BSA. 28 Cells were grown in 5% CO 2 humidified incubator.
Vector construction and production
Construction of pLXie (CUG)13 antisense RNA: A 170-bp DNA fragment was isolated from genomic DNA by PCR using primers 406 and 409 (Mahadevan) , cloned into TA cloning kit. This fragment contains a 22-bp region preceding the repeats, 13 CTG repeats and a 110-bp region following the repeats in the 3 0 UTR of the DMPK mRNA. This fragment was then excised by digestion with BsaMI/Xho and cloned into the HpaI and Xho restriction sites in pLXie. The final construct expresses an antisense RNA complementary to (CUG)13 repeats and to the 110-bp region following the repeats.
Construction of pLXie 5 0 UTR antisense: A 5-kb BamHI fragment from the 5 0 end of the human DMPK gene cloned into pUC18 was a gift from Dr MS Mahadevan (Acc # L08835). A 857-bp DNA fragment (À2169 to À1311) in the 5 0 UTR of the DMPK gene was excised by digestion with XmnI/AflIII, blunted and cloned into the blunted EcoRV restriction site of pcDNA3. The orientation of the fragment was determined by DNA sequencing. The antisense was excised from pcDNA3 by digestion with EcoRI/XhoI and cloned in pLXie at the EcoRI and XhoI restriction sites.
All the constructs were verified by direct sequencing (Perkin Elmer, Foster City, CA, USA). To produce infectious vectors, 293-gpg cells at a density of 10-12 Â 10 6 per 10-cm culture dishes were transfected with 1 mg of pLXie, by using Transfectam (Qiagen). Vectors were harvested at day 7 after the transfection period, in a medium that has been in contact with the cells for 4 days.
Transduction of human primary myoblasts
The supernates containing the pLXie vector were pretreated with 80 mg/ml polybrene, and cells at 60-70% confluence were transduced with pLxie vectors by centrifugation at 800g for 30 min at 201C. This step was repeated 18 h later. The transduced cells were washed and incubated in MCDB120 for 24-36 h. Cells were then trypsinized and GFP-positive cells were isolated by fluorescence-activated-cell-sorting (FACS). GFP-positive cells were grown in a proliferative medium as described above.
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Cell analysis
Cell proliferation was determined by MTT assay. 35 The index of fusion was determined by counting the number of nuclei in multinucleated myotubes and it was expressed as a percentage of the total number of nuclei.
2-deoxy-[ 3 H]deoxyglucose glucose transport: 2-Deoxyglucose uptake was performed according to the procedure described by Sarabia et al,. 36 Myotubes were preincubated for 24 h in serum-free media depleted in insulin and containing 5.5 mM glucose. The cells were then incubated with or without the desired concentration of insulin (0-1 mM) for 45 min at 371C and then, rinsed once with glucose-free HEPES-buffered saline solution and subsequently incubated for 8 min with 10 mM 2-deoxy-[ 3 H]-glucose. After washing, cells were lyzed in 0.05 N NaOH, and the radioactivity was determined by scintillation counting. Non-carrier-mediated uptake was determined in parallel determinations in the presence of 10 mM cytochalasin B and was subtracted from all experimental values. Protein content was determined by the method of Bradford using the Bio-Rad reagent (Bio-Rad Laboratories, Richmond, CA, USA). Glucose transport is expressed throughout in pmol/min/mg protein.
Northern blot analysis
Total RNA was extracted using Trizol reagent (Life Technologies, Inc.) on whole cells. RNA concentrations were determined spectrophotometrically by measuring the A260. In total, 12 mg of RNA was separated on 1.2% agarose gels containing 0.66 M formaldehyde, and transferred to GeneScreen Plus membranes. The recovery of RNAs was determined by hybridization with a 32 Plabeled cyclophilin DNA probe as described. 32 DMPK probe was generated by random priming of 25-50 ng of the DMPK cDNA (BglII-SacI fragment) and hybridization was done overnight at 681C in hybridization buffer (2% SDS/10% dextran sulfate/1 Â SSPE/10 mg/ml salmon sperm DNA/2% Denhart's). Quantitation of relative RNA levels of autoradiograms was determined by densitometry (AlphaImager scan from Alpha Innovatech Corp.). All values were normalized to cyclophilin signal.
Western analysis
To determine CUGBP1 levels in muscle cells, whole cell protein extracts were prepared from normal, DM1 and DM1 myoblasts infected with recombinant retrovirus expressing antisense CUG13. Proteins were separated by 10% polyacrylamide gel electrophoresis with SDS and transferred onto nitrocellulose membrane. CUGBP1 was detected with polyclonal antibodies against CUGBP1 (1:1000) as described.
14 To determine protein loading, the same membrane after CUGBP1 detection was reprobed with antibodies against b-actin, and CUGBP1 levels were calculated as ratio to b-actin.
UV-crosslinking analysis
RNA probe containing 123 CUG repeats was synthesized in in vitro transcription assay (Roech Molecular Biochemical) using 32 P-UTP. Proteins from normal, DM1 and DM1 myoblasts infected with recombinant retrovirus expressing antisense CUG repeats were incubated with radioactive RNA for 30 min at room temperature, and then subjected to UV treatment for 5 min as described. 33 The samples were treated with RNase A and then baded on 10% polyacrylamide gel containing 0.1% SDS. After electrophoresis, proteins were transferred onto nitrocellulose membrane, and subjected to radioautography. After developing, the membranes were stained with Coomassie blue to verify protein loading.
